News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
FDA to Meet on Long-Lasting Zyprexa
January 9, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON -The Food and Drug Administration has scheduled a meeting next month to review the safety and effectiveness of a long-acting version of Eli Lilly & Co.'s schizophrenia drug.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Regulatory
Eli Lilly and Company
MORE ON THIS TOPIC
Neuropsychiatric disorders
Vistagen in freefall as social anxiety drug fails Phase 3
July 1, 2026
·
2 min read
·
Tristan Manalac
Duchenne muscular dystrophy
Sarepta secures early 2027 FDA decision for Duchenne drugs, pushing past confirmatory fail
July 1, 2026
·
2 min read
·
Tristan Manalac
Podcast
Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water
July 1, 2026
·
2 min read
·
Jef Akst
Insights
Golden Triangle still dominates, but talent and capital gaps slow biotech growth
July 1, 2026
·
3 min read
·
Jennifer C. Smith-Parker
